New member state Hungary opens door to non-EU producers
This article was originally published in Clinica
Manufacturers of CE - marked medical devices whose goods are produced outside the EU are on the brink of being able to enjoy for the first time free trade into Hungary without the need to comply with additional regulatory requirements.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.